about
Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology.Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceEnterovirus-infected β-cells induce distinct response patterns in BDCA1+ and BDCA3+ human dendritic cells.CD1 and major histocompatibility complex II molecules follow a different course during dendritic cell maturation.Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.Radical changes in multiple sclerosis pathogenesis.Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy.A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.Protective effects of peroxiredoxin-1 at the injured blood-brain barrier.Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling.NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions.Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets.Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patientsMaturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination.Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study.Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI.Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression.Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma PatientsBDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma PatientsLong Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma PatientsTargeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of CellsTargeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN SecretionSkin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic MelanomaThe C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cellsRoute of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma PatientsWild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide usedHealth-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapyAutologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
P50
Q34673045-124F9ECC-C94D-4684-B968-A63F6786CB58Q35142813-5B5C8E78-BBDC-42D7-A7BF-1EFC38E3735DQ35586004-D3618CD7-A2D2-4083-B554-33ABF1D3A0ECQ35670440-5DE40A47-7E07-45A4-9B63-F07478F3F027Q37702840-B02ED793-E3C4-4E31-9B0D-BBCB65C84593Q37769906-724819DB-109C-44A8-917E-91CEEB02D136Q38206571-D5008FF0-9A38-42A6-8331-C10EDF52C58EQ38208309-2228C5B2-E392-4A4C-9A15-F28F09A252C8Q38365774-5A61545D-6360-4C8A-AC18-1C730C6DA0E2Q38576179-72D776A2-5424-4A2A-84D1-F2B49E8643CCQ39985913-9FA8ADD9-27F2-48AF-9EDB-20889E12D641Q40116310-918FA6AB-8331-49DF-A1A2-DD114F628495Q40310826-42164346-7565-44B7-9A2A-3CABA644BA76Q41835523-5C2FA24E-794C-47F9-BB2E-7C3691DE84C0Q41967129-0B9EED70-55BA-4B4C-B21B-30D95A2A0FD8Q41968893-8A131010-607B-4778-B989-2A9576DB8A8AQ42238407-5F63910F-4F5A-41C9-AAF9-BE3BE1798022Q42969701-56366BA9-1D4E-4454-ABC2-86F860957B6CQ43083716-E7D44418-B0AA-4E98-BCBB-EBC8B771467AQ43946210-AC148D55-78BB-4572-BCFA-33B069E12F3DQ44137387-6C000604-79C2-482F-A213-3C7618D6D434Q44703173-D03E6D6F-A12E-4681-BFE6-7C6A64E40176Q46876439-011BE46F-7E4A-4F0C-86BD-8CBBB4A01776Q46885041-2CC490D9-BFFC-40DC-92CA-A6A66F55D34EQ48657577-4D3F54DC-0A74-4E41-898F-C8255FCCC9FCQ48874616-0FD4F964-EE3B-4E7A-B660-169339C43B5BQ56637518-6731432E-33A8-4BBD-A7BD-52241CE1C701Q57155184-72C96BEA-79B9-4C9A-A3DB-B820812D972FQ57779512-26B28EF3-32C1-46CB-9B7C-FB1C7A3599DEQ58619847-DF94DCEB-A896-4E8C-926C-DB2620259839Q58619874-EEEDAF9F-080F-41FC-9DD2-EA11AB5C5281Q58619877-4AA7BF92-EC33-4B5A-9BD7-DF1353FA1181Q58619897-EBBDF694-0892-428B-BE32-BE3E03B973BCQ58619899-77191BF8-F314-4E28-9D64-A0B79EF20F33Q58619922-915BA1B3-99CD-496B-94A4-3715C555BD80Q58619928-79E89C38-ED82-4F02-9BB9-9D306394C847Q64030269-D5C1DF63-DDC2-458B-AE3A-60E33ACADC03Q92933884-DF2972C2-E270-41DF-9503-AE5058495124
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gerty Schreibelt
@ast
Gerty Schreibelt
@en
Gerty Schreibelt
@es
Gerty Schreibelt
@nl
Gerty Schreibelt
@sl
type
label
Gerty Schreibelt
@ast
Gerty Schreibelt
@en
Gerty Schreibelt
@es
Gerty Schreibelt
@nl
Gerty Schreibelt
@sl
prefLabel
Gerty Schreibelt
@ast
Gerty Schreibelt
@en
Gerty Schreibelt
@es
Gerty Schreibelt
@nl
Gerty Schreibelt
@sl
P1053
A-1260-2016
P106
P21
P31
P3829
P496
0000-0002-0156-8365